All riders still competing in the Tour de France underwent doping tests during Monday's rest day, according to a statement from the International Testing Agency (ITA), the body responsible for anti-doping.

Several teams, including Red Bull-Bora-Hansgrohe which features Belgian Olympic champion Remco Evenepoel, announced Tuesday that their riders were tested the previous evening.

This followed controversial tests conducted in the early hours of Sunday, targeting race leader Tadej Pogačar of Slovenia and his main rival Jonas Vingegaard of Denmark. Notably, Vingegaard withdrew from the Tour after a crash, hours after being woken at 2 a.m. by anti-doping inspectors.

The International Testing Agency said in a statement late Tuesday evening: 'The International Testing Agency (ITA) confirms the implementation of a comprehensive blood sampling campaign under the Athlete Biological Passport (ABP) during the rest day of the Tour de France on July 20, 2026.'

It added: 'The testing campaign covered all riders in the race, as part of the ITA's ongoing anti-doping program based on intelligence gathering and risk assessment during the race.'

The ITA did not disclose any results, and a spokesperson told AFP that processing the results would take weeks.

The agency explained that the Athlete Biological Passport 'is not intended to directly detect a prohibited substance or method,' but rather 'monitors selected biological variables over time to identify changes that may indicate the effects of doping.'

Several riders, including Pogačar and Evenepoel, described the nighttime tests as 'inhumane' and lacking respect for athletes.

The Professional Cyclists' Association (CPA) also criticized the procedures, saying they could negatively affect riders' rest and recovery between the demanding stages of the Tour de France.